1-2 of 2
A. Hilary Calvert
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1b study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI

Branimir Sikic, Heather Wakelee, Margaret Von Mehren, Nancy Lewis, E. Ruth Plummer, A. Hilary Calvert, Norma Lynn Fox, Elizabeth Kumm, Suzanne Jones, Howard Burris
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2007) 6 (11_Supplement): B72.
Published: 01 November 2007
View article titled, A Phase 1b study to assess the safety of lexatumumab, a human monoclonal antibody that activates TRAIL-R2, in combination with gemcitabine, pemetrexed, doxorubicin or FOLFIRI
Journal Articles

Homocysteine and Methylmalonic Acid: Markers to Predict and Avoid Toxicity from Pemetrexed Therapy

Clet Niyikiza, Sharyn D. Baker, David E. Seitz, Jackie M. Walling, Katrina Nelson, James J. Rusthoven, Sally P. Stabler, Paolo Paoletti, A. Hilary Calvert, Robert H. Allen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2002) 1 (7): 545–552.
Published: 01 May 2002
View article titled, Homocysteine and Methylmalonic Acid: Markers to Predict and Avoid Toxicity from Pemetrexed Therapy
Open the PDF for Homocysteine and Methylmalonic Acid: Markers to Predict and Avoid Toxicity from Pemetrexed Therapy in another window